An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

NCT00346632 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

37

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to suboptimal dosing schedule

Conditions

Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Chronic Myelogenous Leukemia

Interventions

DRUG: KW-2449

Sponsor

Kyowa Kirin, Inc.